![Restoration of Li+ pathways in the [010] direction during direct regeneration for spent LiFePO4](http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D5EE00641D)
.jpg)
Human medicines European public assessment report (EPAR): Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.), beclometasone,formoterol, Date of authorisation: 23/04/2018, Revision: 7, Status: Withdrawn
Human medicines European public assessment report (EPAR): Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.), beclometasone,formoterol, Date of authorisation: 23/04/2018, Revision: 7, Status: Withdrawn
Human medicines European public assessment report (EPAR): Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.), beclometasone,formoterol, Date of authorisation: 23/04/2018, Revision: 7, Status: Withdrawn
